Is hypermobile Ehlers‑Danlos syndrome (HEDS) an autoimmune disease, and what are its characteristics and management?

hEDS is NOT an Autoimmune Disease—It is an Inherited Connective Tissue Disorder

Hypermobile Ehlers-Danlos syndrome (hEDS) is fundamentally a hereditary connective tissue disorder characterized by joint hypermobility, tissue fragility, and musculoskeletal symptoms—not an autoimmune condition. However, emerging evidence reveals significant immune dysregulation that may contribute to disease pathophysiology 1, 2.

What hEDS Actually Is

hEDS belongs to a cluster of inherited connective tissue disorders and represents 80-90% of all EDS subtypes 1. The condition is defined by:

• Generalized joint hypermobility (assessed via Beighton score: ≥6/9 in prepubertal children, ≥5/9 from puberty to age 50, ≥4/9 after age 50) 1
• Musculoskeletal manifestations including chronic pain, soft/velvety skin, and tissue fragility 1
• Multisystem involvement affecting gastrointestinal, autonomic, and neuropsychiatric systems 3

The molecular basis remains elusive, unlike other EDS subtypes with defined genetic causes 3. Recent genome-wide association studies identified common variants near ACKR3 (atypical chemokine receptor 3) and SLC39A13 (a zinc transporter), implicating neuroimmune signaling and connective tissue development pathways 3.

The Immune Connection—But Not Autoimmunity

Critical distinction: While hEDS involves immune dysregulation, this does not make it an autoimmune disease. Recent proteomic analysis revealed:

• 35 differentially expressed proteins, with 43% involved in complement cascade and 80% linked to immune, coagulation, or inflammatory pathways 2
• Significant reductions in complement proteins (C1QA, C3, C8A, C8B, C9) 2
• Altered cytokine profiles suggesting dysregulated inflammatory response 2

These findings indicate innate immune dysfunction rather than autoimmune attack on self-tissues 2. The evidence suggests a model of neuroimmune-stromal dysregulation 3, where altered collagen structure triggers fibroblast dysfunction and abnormal mast cell activation 1.

Common Pitfalls in Understanding hEDS

Do not confuse associated conditions with the primary diagnosis. Patients frequently present with:

• POTS (Postural Orthostatic Tachycardia Syndrome): 37.5% of hEDS patients, defined as heart rate increase ≥30 bpm within 10 minutes of standing (≥40 bpm in adolescents 12-19 years) without orthostatic hypotension 1
• MCAS (Mast Cell Activation Syndrome): Characterized by mast cell degranulation triggered by food, heat, emotion, mechanical stimuli, affecting ≥2 body systems 1
• Gastrointestinal symptoms: 98% meet criteria for disorders of gut-brain interaction 1

These represent comorbid conditions with overlapping symptoms, not the core pathology 1.

Clinical Manifestations Beyond Joints

Nearly all patients (98%) experience gastrointestinal symptoms including IBS, gastroparesis, and dysmotility 1. The average patient reports:

• 5.4 joints involved (most commonly shoulder, knee, lumbar spine) 4
• 2.8 comorbid systemic conditions on average 4
• Autonomic dysfunction as the most common comorbidity 4

Genetic correlations exist with myalgic encephalomyelitis/chronic fatigue syndrome, fibromyalgia, depression, anxiety, autism spectrum disorder, migraine, and gastrointestinal diseases 3.

Management Approach

Treatment focuses on symptom management and preventing complications, not immunosuppression:

For Musculoskeletal Symptoms

• Physical therapy emphasizing joint stabilization
• Pain management strategies
• Avoidance of high-impact activities that risk joint injury

For Associated POTS 1

• First-line: Increase fluid intake (2-3 liters daily), salt supplementation (6-10 grams daily), exercise training, compression garments
• Refractory cases: Pharmacological treatments for volume expansion, heart rate control, vasoconstriction with cardiology/neurology consultation

For Associated MCAS 1

• Pharmacological: Histamine receptor antagonists (H1 and H2 blockers), mast cell stabilizers
• Trigger avoidance: Specific foods, alcohol, strong smells, temperature extremes, mechanical friction, emotional stress, certain medications (opioids, NSAIDs, iodinated contrast)

For Gastrointestinal Symptoms 1

• Treat prominent symptoms based on function testing results
• Consider gastroparesis diet (small particle diet)
• Elimination diets (low FODMAP, gluten-free, dairy-free, low-histamine) with nutritional counseling to prevent restrictive eating patterns
• Test for celiac disease earlier in evaluation (not just with diarrhea) 1
• Anorectal manometry for suspected pelvic floor dysfunction 1
• Gastric emptying studies in patients with POTS and upper GI symptoms 1

Diagnostic Considerations

Universal testing for POTS/MCAS is not supported in all hEDS patients 1. Testing should be targeted to those with clinical manifestations:

• For MCAS: Serum tryptase at baseline and 1-4 hours following symptom flares (increases of 20% above baseline plus 2 ng/mL indicate mast cell activation) 1
• For POTS: Tilt table testing or active stand test demonstrating appropriate heart rate criteria

Genetic testing plays a critical role in excluding alternative diagnoses—26.4% of patients meeting hEDS criteria had alternative or additional diagnoses identified through genetic testing requiring distinct management 5.

The pathophysiology involves fascial abnormalities including altered thickness, impaired interfascial gliding, myofibroblast activation, and abnormal tissue stiffness 6, supporting a model of pathological fascial remodeling rather than autoimmune destruction.